Table 9 ADR related to DPP-4i use, N = 105
From: Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital
Parameters/characteristics | n (%) | |
|---|---|---|
ADR occurrence | Saxagliptin | 6 |
Sitagliptin | 3 | |
Linagliptin | 0 | |
Vildagliptin | 3 | |
Types of ADR | Gastrointestinal intolerance | 7 (6.7) |
Dizziness | 3 (2.9) | |
Hypoglycaemia | 1 (1.0) | |
Leg oedema | 1 (1.0) | |
Action taken when ADR occurs | Change to different DPP-4i | 6 (50.0) |
Continue the same DPP-4i | 5 (42.7) | |
Dose reduction | 1 (8.3) | |
Discontinuation of DPP-4i | 0 (0.0) | |
Choice of new DPP-4i | Saxagliptin/Metformin | 4 (50.0) |
Saxagliptin | 1 (33.3) | |
Linagliptin | 1 (16.7) | |